The time factor in oncology: Consequences on tumour volume and therapeutic planning

Giovanni Creton, Mi Benassi, M. Di Staso, G. Ingrosso, C. Giubilei, L. Strigari

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The rules that govern tumour treatment depend largely on clinical stage (tumour volume, localization and/or metastasis presence). These rules are applied assuming that tumor growth is relatively static without considering the time factor, the number of clonogenic cells in the tumour or the volume reduction following initial cytotoxic therapy. Time and neoplastic growth (with a subsequent change in volume) are generally not considered in 90% of clinical trials, where chemotherapy is administered on the first and eighth day and radiotherapy is carried out five days a week with different schedules. In the clinical situation, however, a tumour has more complex growth times that should be appropriately assessed to improve the treatment results (1). The aim of this paper is to stress the influence of the time factor to optimize the schedule of the cytotoxic therapies, based on different mathematical models developed to describe the tumour growth. To better understand the role of the neoplastic growth at its different clinical stages and the subsequent response to cytotoxic therapies, several elements concerning such growth should be thoroughly analyzed.

Original languageEnglish
Pages (from-to)557-573
Number of pages17
JournalJournal of Experimental and Clinical Cancer Research
Volume25
Issue number4
Publication statusPublished - Dec 2006

Fingerprint

Tumor Burden
Growth
Neoplasms
Appointments and Schedules
Therapeutics
Theoretical Models
Radiotherapy
Cell Count
Clinical Trials
Neoplasm Metastasis
Drug Therapy

Keywords

  • Cytotoxic therapies
  • Doubling time
  • Gompertz's model
  • IORT
  • Neoplastic growth
  • Time interval

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

The time factor in oncology : Consequences on tumour volume and therapeutic planning. / Creton, Giovanni; Benassi, Mi; Di Staso, M.; Ingrosso, G.; Giubilei, C.; Strigari, L.

In: Journal of Experimental and Clinical Cancer Research, Vol. 25, No. 4, 12.2006, p. 557-573.

Research output: Contribution to journalArticle

Creton, G, Benassi, M, Di Staso, M, Ingrosso, G, Giubilei, C & Strigari, L 2006, 'The time factor in oncology: Consequences on tumour volume and therapeutic planning', Journal of Experimental and Clinical Cancer Research, vol. 25, no. 4, pp. 557-573.
Creton, Giovanni ; Benassi, Mi ; Di Staso, M. ; Ingrosso, G. ; Giubilei, C. ; Strigari, L. / The time factor in oncology : Consequences on tumour volume and therapeutic planning. In: Journal of Experimental and Clinical Cancer Research. 2006 ; Vol. 25, No. 4. pp. 557-573.
@article{498fd01a73f643298269be9d62ac21d1,
title = "The time factor in oncology: Consequences on tumour volume and therapeutic planning",
abstract = "The rules that govern tumour treatment depend largely on clinical stage (tumour volume, localization and/or metastasis presence). These rules are applied assuming that tumor growth is relatively static without considering the time factor, the number of clonogenic cells in the tumour or the volume reduction following initial cytotoxic therapy. Time and neoplastic growth (with a subsequent change in volume) are generally not considered in 90{\%} of clinical trials, where chemotherapy is administered on the first and eighth day and radiotherapy is carried out five days a week with different schedules. In the clinical situation, however, a tumour has more complex growth times that should be appropriately assessed to improve the treatment results (1). The aim of this paper is to stress the influence of the time factor to optimize the schedule of the cytotoxic therapies, based on different mathematical models developed to describe the tumour growth. To better understand the role of the neoplastic growth at its different clinical stages and the subsequent response to cytotoxic therapies, several elements concerning such growth should be thoroughly analyzed.",
keywords = "Cytotoxic therapies, Doubling time, Gompertz's model, IORT, Neoplastic growth, Time interval",
author = "Giovanni Creton and Mi Benassi and {Di Staso}, M. and G. Ingrosso and C. Giubilei and L. Strigari",
year = "2006",
month = "12",
language = "English",
volume = "25",
pages = "557--573",
journal = "Journal of Experimental and Clinical Cancer Research",
issn = "0392-9078",
publisher = "BioMed Central Ltd.",
number = "4",

}

TY - JOUR

T1 - The time factor in oncology

T2 - Consequences on tumour volume and therapeutic planning

AU - Creton, Giovanni

AU - Benassi, Mi

AU - Di Staso, M.

AU - Ingrosso, G.

AU - Giubilei, C.

AU - Strigari, L.

PY - 2006/12

Y1 - 2006/12

N2 - The rules that govern tumour treatment depend largely on clinical stage (tumour volume, localization and/or metastasis presence). These rules are applied assuming that tumor growth is relatively static without considering the time factor, the number of clonogenic cells in the tumour or the volume reduction following initial cytotoxic therapy. Time and neoplastic growth (with a subsequent change in volume) are generally not considered in 90% of clinical trials, where chemotherapy is administered on the first and eighth day and radiotherapy is carried out five days a week with different schedules. In the clinical situation, however, a tumour has more complex growth times that should be appropriately assessed to improve the treatment results (1). The aim of this paper is to stress the influence of the time factor to optimize the schedule of the cytotoxic therapies, based on different mathematical models developed to describe the tumour growth. To better understand the role of the neoplastic growth at its different clinical stages and the subsequent response to cytotoxic therapies, several elements concerning such growth should be thoroughly analyzed.

AB - The rules that govern tumour treatment depend largely on clinical stage (tumour volume, localization and/or metastasis presence). These rules are applied assuming that tumor growth is relatively static without considering the time factor, the number of clonogenic cells in the tumour or the volume reduction following initial cytotoxic therapy. Time and neoplastic growth (with a subsequent change in volume) are generally not considered in 90% of clinical trials, where chemotherapy is administered on the first and eighth day and radiotherapy is carried out five days a week with different schedules. In the clinical situation, however, a tumour has more complex growth times that should be appropriately assessed to improve the treatment results (1). The aim of this paper is to stress the influence of the time factor to optimize the schedule of the cytotoxic therapies, based on different mathematical models developed to describe the tumour growth. To better understand the role of the neoplastic growth at its different clinical stages and the subsequent response to cytotoxic therapies, several elements concerning such growth should be thoroughly analyzed.

KW - Cytotoxic therapies

KW - Doubling time

KW - Gompertz's model

KW - IORT

KW - Neoplastic growth

KW - Time interval

UR - http://www.scopus.com/inward/record.url?scp=33846478655&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846478655&partnerID=8YFLogxK

M3 - Article

C2 - 17310848

AN - SCOPUS:33846478655

VL - 25

SP - 557

EP - 573

JO - Journal of Experimental and Clinical Cancer Research

JF - Journal of Experimental and Clinical Cancer Research

SN - 0392-9078

IS - 4

ER -